medRxiv preprint doi: https://doi.org/10.1101/2024.03.25.24304711; this version posted March 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Results of a nationally representative seroprevalence survey of chikungunya virus in Bangladesh

- 3
- 4 Sam W. Allen¹, Gabriel Ribeiro Dos Santos¹, Kishor K Paul^{2,3,4}, Repon Paul^{4,5}, Ziaur Rahman⁴,
- 5 Mohammad Shafiul Alam⁴, Mahmudur Rahman⁶, Hasan Mohammad Al-Amin^{4,7,8}, Jessica
- 6 Vanhomwegen¹⁰, Taylor Smull¹¹, Kyu Han Lee¹², Emily S. Gurley^{11*}, Henrik Salje^{1,11*}
- 7
- 8 1. Department of Genetics, University of Cambridge, Cambridge, UK
- 9 2. Kirby Institute, University of New South Wales, Sydney, Australia
- 10 3. School of Population Health, University of New South Wales, Sydney, Australia
- 11 4. icddr,b, Dhaka, Bangladesh
- 12 5. Centre for Big Data Research in Health, University of New South Wales, Sydney, Australia
- 13 6. IEDCR, Dhaka, Bangladesh
- 14 7. QIMR Berghofer Medical Research Institute, Queensland, Australia
- 15 8. School of the Environment, The University of Queensland, Queensland, Australia
- 16 10. Institut Pasteur, Paris, France
- 17 11. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore,
 18 USA
- 19 12. Emory Global Health Institute, Emory University, Atlanta, USA
- 20
- 21 22

* joint senior authors

23 24

25 Abstract26

27 Chikungunya virus (CHIKV) is responsible for a rapidly increasing but poorly understood infection 28 burden globally. Bangladesh experienced its first reported outbreak in 2008. Despite a number of 29 subsequent isolated outbreaks, culminating in an enormous nationwide epidemic in 2017, very little is 30 known about the burden or dynamics of chikungunya within the country, and the risk factors for 31 infection. We conducted a nationally representative seroprevalence survey in 2016 in 70 randomly 32 selected communities across the country. Individuals provided blood samples, which were tested for 33 the presence of IgG antibodies to CHIKV. We also trapped and speciated mosquitoes. We found that 34 69/2,938 (2.4%) of individuals were seropositive to CHIKV. Seropositive individuals were 35 concentrated in the centre and south of the country. We found that being seropositive to dengue virus 36 (aOR 3.11 [95% CIs: 1.17 – 24.45]) and male sex (aOR 0.29 [95% CIs: 0.01 – 0.96]), were significantly 37 associated with CHIKV seropositivity, however, Aedes presence, income, and travel history were not. 38 Using a spatial prediction model, we estimate that at the time of the study, 4.99 million people in the 39 country had been infected with CHIKV. These findings highlight high population susceptibility prior 40 to the major outbreak in 2017 and that historic outbreaks must have been spatially isolated.

- 41 42
- 43 Keywords: chikungunya; seroprevalence, Bangladesh

- 46
- 47
- 48
- 49 50

51 Introduction

52

53 Chikungunya virus (CHIKV) is an Aedes-transmitted arbovirus first detected in Tanzania in 1953 which 54 has since spread to the rest of Africa, Asia and South America, as well as sporadic outbreaks elsewhere 55 [1]. The hallmark symptoms of chikungunya are abrupt onset of fever and joint pain [2,3], commonly 56 accompanied by a rash [4]. The clinical presentation of chikungunya in humans is similar to that of 57 dengue and a range of other illnesses, so is often misdiagnosed [2,5–9]. Around half of infected 58 individuals suffer long-term effects, the most common of which is arthralgia [10–15] that can continue 59 for months or even years post-infection, severely decreasing quality of life [16–18]. High attack rates 60 coupled with frequent severe, persistent symptoms means that CHIKV outbreaks can place a large 61 burden on communities, especially in lower-middle-income countries [2].

62

63 Limited access to testing and misdiagnoses mean that entire CHIKV epidemics are frequently missed, 64 especially in lower-middle-income countries [19,20] and we rarely have a good understanding of the 65 underlying burden from CHIKV in any affected setting, as well as individual-, household- and 66 population-level predictors of infection risk. This critical knowledge gap means we do not know where 67 to appropriately target interventions. This is becoming increasingly relevant, with the licensure of the 68 first chikungunya vaccines expected in the near future and the demonstration that the targeted release 69 of Wolbachia-infected mosquitoes can reduce incidence [21,22]. In this context, seroprevalence studies can help, especially as CHIKV infection appears to result in long-lasting and immunising 70 71 antibodies[23]. By measuring the presence of antibodies in the population, we can quantify the 72 underlying level of infection history in a population[20]. Further, by combining the results of 73 seroprevalence studies from multiple locations with mathematical models, we can estimate the burden 74 across the population, and the changing level of immunity [24]. 75

76 Here we focus on Bangladesh. CHIKV was first identified in Bangladesh in 2008 during an outbreak 77 in the northwest of the country in two villages near the Indian border [25]. Subsequently, there were 78 localised outbreaks detected between 2011 and 2016 [2,26]. In 2017, Bangladesh experienced a far 79 larger outbreak, with infections reported nationwide with as many as a million reported cases in total 80 [2,27,28]. However, it remains unclear if there was substantial transmission across the country prior to 81 the large outbreak in 2017. In this project, we present the results of a nationally representative 82 seroprevalence study from Bangladesh. We visited communities around the country in 2016, allowing 83 us to quantify the level of transmission, identify risk factors for infection, and the level of immunity 84 prior to the major outbreak.

85 86

87 88

Results 89

90 We visited 70 randomly selected communities in Bangladesh. We collected blood and administered 91 questionnaires from 2,938 individuals. Simultaneously, we collected mosquitoes using BG-Sentinel 92 traps during our survey. There was a mean of 42 participating individuals per community (range 39-93 57), and a mean of 10 participating households per community (range 10-12). The mean age of 94 participants was 30 and 52% of participants were female. Our IgG Luminex-based antibody assay 95 divided individuals into seropositive and seronegative individuals (Figure S1). Among the participants, 96 2.4% were seropositive to CHIKV, with all seropositive individuals coming from 16 communities (23% 97 of all communities), concentrated in the central and south of the country. Among seropositive 98 communities, mean seropositivity was 10.45%, ranging from 2.08 to 39.02%. Notably, a single 99 individual from the 3 communities in Dhaka city were seropositive. Seropositivity was largely 100 consistent across different age groups, except for those aged under five years in age, who had a 101 seropositivity of 0% compared to 2.4% for those over five years (p-value 0.26) (Table 1). We used 102 logistic regression to identify covariates associated with being seropositive. We compared models with 103 or without a spatial covariance term, as well as models with or without household and community level 104 random intercepts. The best fitting model, as measured by WAIC (Watanabe-Akaike information 105 criterion, a measure for model comparison), included household and community level random

106 intercepts, however, covariate estimates were largely consistent across the different models considered 107 (Figure S2).

108

109 We compared a suite of models to identify individual-, household- and community- level covariates 110 linked to CHIKV seropositivity. These models either included or did not include household and community random effects and a spatial field. The best fitting model had both household and 111 112 community random effects but no spatial field (Table S1). In this model, we found most factors were not associated with CHIKV seropositivity. This includes the presence of Aedes aegypti and Ae. 113 114 albopictus in the community, population density, household income and travel history. However, being 115 aged under 5 years (aOR: 0.00, 95% CI: 0.00 - 0.0003), being seropositive for dengue virus (aOR: 3.11, 116 95% CI: 1.17 – 24.45), male sex (aOR: 0.29, 95% CI: 0.01 – 0.96) and household ownership (aOR: 117 0.06, 95% CI: 0.00 – 0.81) were significantly associated. Either Ae. aegypti or Ae. albopictus was found 118 in 46 communities (66% of communities) (Figure S3).

119

120 We next explored whether within the communities where CHIKV seropositivity was detected, living 121 with a seropositive individual was a risk factor for being seropositive. We found that within these 122 communities, individuals who lived with a seropositive householder member had 2.80 (95% CIs: 1.47 123 -4.85) times the probability of being seropositive as compared to individuals living with only 124 seronegative individuals.

125

126 To estimate the overall seropositivity across the country, we used a spatial prediction model. We used 127 the estimated population distribution in the country to identify the number of infected individuals. 128 Overall, we estimate that 4.99 million people (95% CI: 4.89 - 5.08 million) in Bangladesh had been 129 infected with chikungunya at some point in their lives as of 2016, with the highest risk concentrated to 130 a few focal hotspots (Figure 2A). This equates to about 2.49% (95% CI: 2.45 - 2.54%) of the national 131 population, consistent with the estimate produced using the crude proportion seropositive among 132 individuals in the serosurvey (2.35% of the population, or about 4.70 million individuals). To validate 133 our spatial prediction model, we removed all data from a subset of individual communities in turn from 134 our model and used the remaining data to fit a new model. We then used the fitted model to predict in 135 the removed locations. We found we could accurately predict seropositivity in the removed locations 136 (Pearson correlation of 0.95) (Figure 2B).

137 138

139 Discussion

140

141 The results from this first nationally-representative serosurvey of CHIKV infection in Bangladesh 142 demonstrate that by 2016, CHIKV had been present in parts of the country, especially the South. 143 Overall, only a relatively small proportion of the population, representing around 5 million individuals, 144 had previously been infected. The high level of population susceptibility at this time can help explain 145 the magnitude and spatial extent of the subsequent major outbreak in 2017.

146

147 CHIKV seropositivity was relatively constant across age groups, which indicates that individuals of all 148 ages have had the same cumulative exposure to risk of infection. This is indicative of a recent emergence 149 of CHIKV in Bangladesh, though the decreased seropositivity among those aged under five suggests 150 limited exposure in the years immediately preceding the serosurvey. We explored a wide range of 151 individual-, household- and community- level risk factors to identify drivers of infection risk. Being 152 seropositive to dengue virus, another virus transmitted by the same vectors, was an important predictor. 153 This highlights the overlapping risk across Aedes-transmitted arboviruses, as previously identified 154 elsewhere [29]. We identified a strong effect of the household, with individuals much more likely to be 155 seropositive if they lived with other seropositive individuals. This finding is consistent with previous 156 findings from Bangladesh and elsewhere that have identified the limited flight range of the vector as 157 driving household infection risk, as biting typically occurs in the peridomestic environment [30]. A 158 strong correlation of serostatus by household has also been observed with dengue virus [31]. Sex was 159 another notable predictor, consistent with results from both Bangladesh and elsewhere that have 160 consistently shown infection risk is higher among females [19,30,32–34]. It has been suggested that

161 differences in mobility patterns may explain this increased risk, with women in Bangladesh spending 162 more time in and around the home where mosquitoes reside [30].

163

Our results suggest that while prior to 2017 CHIKV outbreaks in Bangladesh have been spatially 164 constrained, there was always the risk of a widespread epidemic. It remains unclear why prior outbreaks 165 166 in the country died out without spreading widely. We identified either Ae. aegypti or Ae. albopictus 167 mosquitoes in most communities, suggesting that conditions were suitable for transmission across the 168 country. Introductions may have previously been in rural communities, which are less connected to 169 urban hubs, and potentially died out from entering cooler parts of the year [30]. As population mobility 170 continues to increase, we can expect even wider spread of both Aedes vectors and a concurrent increase 171 in arbovirus outbreak risk [35].

172

This project highlights the utility of nationally representative seroprevalence studies, especially when 173 174 combined with mathematical models. Using a sampling frame of all communities in Bangladesh allows 175 us to generalise to the wider country. These same samples were used to create risk maps for a wide 176 range of other pathogens, including cholera, dengue, and hepatitis E [24,36,37]. Further, the increased 177 use of multiplex serology allows the parallel testing of multiple pathogens, maximising insights from 178 individual blood draws, and limiting the need for numerous freeze-thaw cycles.

179

180 We note that our modelled estimate of seropositivity at the national level was very consistent with the 181 crude level of seropositivity in our sample set (2.49% vs 2.35%). It is certainly possible that we did not 182 sample communities affected by localised outbreaks but those outbreaks would not markedly change 183 our estimates for the overall population level immunity for Bangladesh. Selection bias may have arisen 184 in that individuals who were away from communities during visits, and hence more likely to travel 185 frequently, may not have been able to participate. However, to minimise this risk, the study team 186 arranged to visit households again when members were expected to return from travel. The travel 187 covariate is also limited in that the questionnaire asked about most recent travel outside the community, 188 which does not provide information on frequency, reason or destination of travel. All of these could be 189 relevant to CHIKV infection risk. 190

191 In conclusion, we demonstrate high CHIKV susceptibility across Bangladesh prior to the major 192 outbreak in 2017, and that prior outbreaks were largely spatially isolated in nature. Given the potential 193 for large outbreaks, Bangladesh should be prioritised for new interventions, such as vaccines and 194 Wolbachia-based vector control, as they become available.

4

195

196

medRxiv preprint doi: https://doi.org/10.1101/2024.03.25.24304711; this version posted March 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

207 **Methods**

208

209 Data collection 210

The protocol of the study has been described elsewhere [24]. Briefly, to obtain a nationally-211 212 representative sample, 70 of the 97,162 communities listed in the 2011 census were selected at random, 213 with the likelihood of selection being proportional to population size. Each community was visited by 214 the study team, who spent at least five days within each community. Visits occurred during October 215 2015 to January 2016. A further visit was made to communities where no Aedes had been previously 216 trapped, during June and July 2016 for additional mosquito collection. Communities where Aedes were 217 still not found after the second visit were defined as having an absence of A. *aegypti* and A. *albopictus*. 218 The study team randomly selected at least ten households from each community. The heads of selected 219 households were informed of the study and invited to participate. If they agreed, all other members of 220 the household aged over six months were also invited to participate. Data collection was deemed to be 221 complete for a community when at least 40 serum samples from at least 10 households were obtained.

222

223 The head of each participating household was led through a household questionnaire with a variety of 224 questions regarding socio-economic status, such as education level, estimated household income and 225 access to electricity. In addition, this questionnaire asked whether households had used any form of 226 mosquito control in the last week and whether any member of the household owned land away from 227 their home [33].

228

229 Each consenting household member (including the household head) was also guided through an 230 individual-level questionnaire. If individuals were too young to answer this by themselves, an older 231 household member was asked to answer on their behalf. These questionnaires covered demographic 232 questions, such as age and sex, and also asked when participants had last travelled outside of the 233 community [33].

234

235 All individuals who provided consent also had 5 ml of venous blood withdrawn by a phlebotomist. 236 These blood samples were centrifuged and serum was then extracted separately and shipped in nitrogen 237 dry shippers to icddr, b (International Centre for Diarrhoeal Disease Research, Bangladesh) laboratories 238 in Dhaka. Individuals who were ill at the time of the survey were excluded from serum sampling. All 239 serum samples were tested for antibodies against chikungunya to identify evidence of prior infection. 240 This was done using a microsphere-based multiplex immuno-assay (MMIA) that measured the 241 fluorescence intensity to both the recombinant E2 glycoprotein of the chikungunya virus and the 242 background level of antibody activity at the individual level using a recombinant human O⁶-243 Methylguanine-DNA Methyltransferase protein (SNAP-tag). To determine CHIKV seropositive we 244 first calculated the ratio between the fluorescence intensity to CHIKV and the control MGMT protein, 245 and used a cut point of 5.5 to identify those with a history of CHIKV exposure (Figure S1). It has 246 previously been estimated that a ratio of 5.5 on a linear scale ($\sim 1.70 \log$ scale) is the threshold for the 247 MMIA to achieve 95% sensitivity and specificity (personal communication) [19]. 248

- 249 **Regression** analyses
- 250

251 We used the R-INLA package, which applies the INLA (Integrated nested Laplace approximation) 252 method. INLA is a Bayesian approach to statistical inference for Gaussian Markov Random Field 253 (GMRF) models [38]. A key benefit of INLA is that it can accommodate a range of GMRF models, 254 including those with a spatial component. R-INLA allows these to be added to the model as random 255 effects. This means that the spatial autocorrelation inherent in epidemiological data can be accounted 256 for to isolate out the role of random spatial variation [39]. We modelled the dependence of two 257 observations in this distribution using a covariance function, with the Matérn covariance function. R-258 INLA's default priors were used beyond the setting of the spatial field, where a fixed smoothness parameter of $\langle = 2 \rangle$ was set. This represents a moderately smooth spatial field, and is a commonly selected 259 260 value [40].

262 Covariates were divided into individual-level (age, sex, dengue serostatus and last time left 263 community), household-level (income, highest education level achieved by head of household, 264 electricity in home, own home, own land away from the home and use of mosquito control in the last 265 week) and community level (Ae. aegypti captured in the community, Ae. albopictus captured in the 266 *community*, division and log population density). Firstly, each covariate was included in a univariate 267 logistic regression using R-INLA to assess individual relationships with serostatus. Random intercepts 268 were also included for both the household and the community to account for correlation of observations 269 within these sites. Following this, all covariates were included in a multivariable analysis. This 270 generated an odds ratio and 95% confidence interval for each covariate from both univariate regression, 271 and an adjusted odds ratio and 95% confidence interval from multivariable regression.

272

273 To explore the importance of the spatial correlation structure and the random household and community 274 intercepts, additional models with different combinations of these included were also built. In total, five 275 models were created:

- 276 1. The base model, featuring a Matérn spatial correlation structure, a random community intercept 277 and a random household intercept.
- 278 2. A Matérn spatial correlation structure and a random household intercept only.
- 279 3. A Matérn spatial correlation structure and a random community intercept only.
- 280 4. A Matérn spatial correlation structure only.
- 281 5. Random household and community intercepts only.

283 Using the base model, the percentage of variance explained by each spatial correlation structure, random 284 community intercept and random household intercept was determined. A model without any of these 285 three was first run, and the variance calculated by taking the mean of the squared residuals. The three 286 random effects were then added one-by-one. Each time, the variance was calculated and the percentage 287 of the variance in the original model that the new model explained was estimated, to try and understand 288 the impact of each addition. This was repeated both by adding the random community intercept before 289 the random household intercept, and vice-versa.

290 291

297

282

292 Household infection risk 293

294 To investigate whether living with a seropositive individual was a risk factor for being seropositive 295 oneself, the risk ratio for living with a seropositive individual was calculated in the subset of 296 communities with at least one seropositive individual. The risk ratio was then calculated as follows:

Risk Ratio
$$=\frac{a}{b}$$

298 299 where.

300 a = the proportion of seropositive individuals living with seropositive individuals

301 b = the proportion of seropositive individuals living with seronegative individuals

303 This risk ratio was first calculated, and then bootstrapped for 1000 iterations to generate a distribution 304 of estimates, from which a mean and 95% confidence intervals were extracted.

305

308

313

314

302

306 307 Mapping chikungunya virus risk across Bangladesh

309 Seroprevalence by community was mapped by community to visualise the general spatial distribution 310 of chikungunya in 2015/2016. Seroprevalence was defined as the number of individuals with detectable 311 anti-chikungunya virus antibodies, expressed as a proportion of the total number of individuals 312 surveyed in that community, calculated as follows:

> $seroprevalence = \frac{number \ of \ seropositive \ individuals}{1}$ total population

medRxiv preprint doi: https://doi.org/10.1101/2024.03.25.24304711; this version posted March 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 315
- 316 95% confidence intervals were also calculated for community seroprevalence using the Clopper-317 Pearson estimation method which is based on the exact binomial distribution (66). Seroprevalence was 318 calculated for each community in the study and mapped to visualise spatial trends.
- 319

320 To explore infection risk across Bangladesh, a grid of 1 km x 1 km cells was placed over the country. 321 A Bayesian framework featuring a Matérn spatial correlation structure was used to fit the model. 322 Covariates from the multivariable regression could not be added to the spatial prediction because values 323 for these covariates are not available for areas outside the study sites. Salje et al. [24] found that the 324 inclusion of additional covariates (e.g. age and sex) beyond the spatial covariance term that can be 325 obtained from demographic data did not markedly improve predictive accuracy, so these were not added 326 to reduce unnecessary model complexity. The model was then fit to the 1 km x 1 km grid across the 327 country to predict the seroprevalence in each of these cells.

328

329 To estimate the total number of people ever infected with CHIKV in Bangladesh at the time of the 330 survey, the population density in each cell was multiplied by the fitted seroprevalence in each cell. 331 Confidence intervals were generated by taking the 0.025 and 0.975 estimates from the model and 332 applying the same technique.

333

334 To test the predictive performance model, a cross validation was performed. 1000 iterations were 335 performed, with ten of the 70 communities left out during model fitting each run. The model was then 336 used to predict the seroprevalence in the ten test communities. The mean predicted seroprevalence for 337 each community was then used to generate an estimated seroprevalence, which was compared to the 338 observed seroprevalence in each of the held out communities.

- 339
- 340
- 341 Ethical clearance
- 342

343 The icddr,b and CDC ethical review boards approved of this study (protocol number PR-14058). All 344 participating adults gave written informed consent. Children involved in the study had written, informed

345 consent provided on their behalf by parents/guardians. 346

347 References

- 348 Zeller H, Van Bortel W, Sudre B. Chikungunya: Its History in Africa and Asia and Its Spread to 1. 349 New Regions in 2013-2014. J Infect Dis. 2016; 214(suppl 5):S436–S440.
- 350 Anwar S, Taslem Mourosi J, Khan MF, Ullah MO, Vanakker OM, Hosen MJ. Chikungunya 2. 351 outbreak in Bangladesh (2017): Clinical and hematological findings. PLoS Negl Trop Dis. 2020; 352 14(2):e0007466.
- 353 3. Suhrbier A, Jaffar-Bandjee M-C, Gasque P. Arthritogenic alphaviruses--an overview. Nat Rev 354 Rheumatol. 2012; 8(7):420–429.
- 355 Nsoesie EO, Kraemer MU, Golding N, et al. Global distribution and environmental suitability 4. 356 for chikungunya virus, 1952 to 2015. Euro Surveill [Internet]. 2016; 21(20). Available from: 357 http://dx.doi.org/10.2807/1560-7917.ES.2016.21.20.30234
- 358 5. Girard M, Nelson CB, Picot V, Gubler DJ. Arboviruses: A global public health threat. Vaccine. 359 2020; 38(24):3989-3994.
- 360 6. Morrison TE. Reemergence of chikungunya virus. J Virol. 2014; 88(20):11644–11647.
- 361 7. Reller ME, Akoroda U, Nagahawatte A, et al. Chikungunya as a cause of acute febrile illness in 362 southern Sri Lanka. PLoS One. 2013; 8(12):e82259.
- 363 Sy AK, Chan V, Bautista A, Capeding MR. Prevalence of chikungunya virus infection among 8. 364 suspected dengue pediatric patients in 3 regional hospitals in the Philippines. Int J Infect Dis. 365 **2012**; 16:e112.
- 366 Hossain MS, Hasan MM, Islam MS, et al. Chikungunya outbreak (2017) in Bangladesh: Clinical 9. 367 profile, economic impact and quality of life during the acute phase of the disease. PLoS Negl 368 Trop Dis. 2018; 12(6):e0006561.
- 369 10. Puntasecca CJ, King CH, LaBeaud AD. Measuring the global burden of chikungunya and Zika 370 viruses: A systematic review. PLoS Negl Trop Dis. 2021; 15(3):e0009055.
- 371 11. Rodríguez-Morales AJ, Calvache-Benavides CE, Giraldo-Gómez J, et al. Post-chikungunya 372 chronic arthralgia: Results from a retrospective follow-up study of 131 cases in Tolima, 373 Colombia. Travel Med Infect Dis. 2016; 14(1):58–59.
- 374 12. Rodriguez-Morales AJ, Restrepo-Posada VM, Acevedo-Escalante N, et al. Impaired quality of 375 life after chikungunya virus infection: a 12-month follow-up study of its chronic inflammatory 376 rheumatism in La Virginia, Risaralda, Colombia. Rheumatol Int. 2017; 37(10):1757–1758.
- 377 13. Kirkland K, Brantley JK, Handey GM. Family medicine education in Alabama. Ala Med. 1989; 378 59(6):26, 28–9.
- 379 14. Tritsch SR, Encinales L, Pacheco N, et al. Chronic Joint Pain 3 Years after Chikungunya Virus 380 Infection Largely Characterized by Relapsing-remitting Symptoms. J Rheumatol. 2020; 381 47(8):1267-1274.
- 382 15. Genderen FT van, Krishnadath I, Sno R, Grunberg MG, Zijlmans W, Adhin MR. First Chikungunya Outbreak in Suriname; Clinical and Epidemiological Features. PLoS Negl Trop 383 384 Dis. **2016**; 10(4):e0004625.
- 385 16. Moro ML, Grilli E, Corvetta A, et al. Long-term chikungunya infection clinical manifestations 386 after an outbreak in Italy: a prognostic cohort study. J Infect. 2012; 65(2):165–172.

- 387 17. Couturier E, Guillemin F, Mura M, et al. Impaired quality of life after chikungunya virus 388 infection: a 2-year follow-up study. Rheumatology . 2012; 51(7):1315–1322.
- 389 18. O'Driscoll M, Salje H, Chang AY, Watson H. Arthralgia resolution rate following chikungunya 390 virus infection. Int J Infect Dis. 2021; 112:1-7.
- 391 19. Lim JK, Ridde V, Agnandji ST, et al. Seroepidemiological Reconstruction of Long-term 392 Chikungunya Virus Circulation in Burkina Faso and Gabon. J Infect Dis. 2023; 227(2):261–267.
- 393 20. Salje H, Cauchemez S, Alera MT, et al. Reconstruction of 60 Years of Chikungunya 394 Epidemiology in the Philippines Demonstrates Episodic and Focal Transmission. J Infect Dis. 395 2016; 213(4):604–610.
- 396 21. Schneider M, Narciso-Abraham M, Hadl S, et al. Safety and immunogenicity of a single-shot 397 live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-398 controlled, phase 3 trial. Lancet. 2023; 401(10394):2138-2147.
- 399 22. Ribeiro dos Santos G, Durovni B, Saraceni V, et al. Estimating the effect of the wMel release 400 programme on the incidence of dengue and chikungunya in Rio de Janeiro, Brazil: a 401 spatiotemporal modelling study. Lancet Infect Dis. 2022; 22(11):1587-1595.
- 402 23. Yoon I-K, Srikiatkhachorn A, Alera MT, Fernandez S, Cummings DAT, Salje H. Pre-existing 403 chikungunya virus neutralizing antibodies correlate with risk of symptomatic infection and 404 subclinical seroconversion in a Philippine cohort. Int J Infect Dis. 2020; 95:167–173.
- 405 24. Salje H, Paul KK, Paul R, et al. Nationally-representative serostudy of dengue in Bangladesh 406 allows generalizable disease burden estimates. Elife [Internet]. 2019; 8. Available from: 407 http://dx.doi.org/10.7554/eLife.42869
- 408 25. Khatun S, Chakraborty A, Rahman M, et al. An Outbreak of Chikungunya in Rural Bangladesh, 409 2011. PLoS Negl Trop Dis. 2015; 9(7):e0003907.
- 410 26. Wahid B, Ali A, Rafique S, Idrees M. Global expansion of chikungunya virus: mapping the 64-411 year history. Int J Infect Dis. 2017; 58:69-76.
- 412 27. Kabir I, Dhimal M, Müller R, Banik S, Haque U. The 2017 Dhaka chikungunya outbreak. Lancet 413 Infect Dis. 2017; 17(11):1118.
- 414 28. Islam MT, Atiqul Haque M, Anjum A, et al. Seroprevalence of Chikungunya Virus Infection in 415 an Urban Slum Population of Bangladesh: A Cross-Sectional Study. J Curr Adv Med Res. 2022; 416 9(1):3-8.
- 417 29. Rodríguez-Barraquer I, Solomon SS, Kuganantham P, et al. The Hidden Burden of Dengue and 418 Chikungunya in Chennai, India. PLoS Negl Trop Dis. 2015; 9(7):e0003906.
- 419 30. Salje H, Lessler J, Paul KK, et al. How social structures, space, and behaviors shape the spread 420 of infectious diseases using chikungunya as a case study. Proc Natl Acad Sci U S A. 2016; 421 113(47):13420–13425.
- 422 31. Santos GR dos, Santos GR dos, Buddhari D, et al. Individual, Household, and Community 423 Drivers of Dengue Virus Infection Risk in Kamphaeng Phet Province, Thailand [Internet]. The 424 Journal of Infectious Diseases. 2022. p. 1348–1356. Available from: 425 http://dx.doi.org/10.1093/infdis/jiac177
- 426 32. Mdho R, Patwary MH, Imtiaz A, et al. Seroprevalence of Chikungunya during Outbreak in 427 Dhaka, Bangladesh in 2017. Journal of Virology & Antiviral Research [Internet]. SciTechnol; 428 2018 [cited 2023 Nov 3]; 2018. Available from: https://www.scitechnol.com/peer-

review/seroprevalence-of-chikungunya-during-outbreak-in-dhaka-bangladesh-in-2017 UNsR.php?article_id=8265

- 431 33. Shourav AH, Murshida Mahbub M, Yasmin M, Ahsan CR, Nessa J. Seroepidemiology of
 432 Chikungunya Fever in Dhaka, Bangladesh: A Crosssectional Study. Banglad J Microbiol. 2021;
 433 38(2):79–85.
- 434 34. Hozé N, Salje H, Rousset D, et al. Reconstructing Mayaro virus circulation in French Guiana
 435 shows frequent spillovers. Nat Commun. 2020; 11(1):2842.
- 436 35. Mahmud AS, Kabir MI, Engø-Monsen K, et al. Megacities as drivers of national outbreaks: The
 437 2017 chikungunya outbreak in Dhaka, Bangladesh. PLoS Negl Trop Dis. 2021; 15(2):e0009106.
- 438 36. Azman AS, Lauer SA, Bhuiyan TR, et al. Vibrio cholerae O1 transmission in Bangladesh:
 439 insights from a nationally representative serosurvey. Lancet Microbe. 2020; 1(8):e336–e343.
- 440 37. Azman A, Paul KK, Bhuiyan TR, et al. Hepatitis E in Bangladesh: Insights from a National
 441 Serosurvey. medRxiv [Internet]. Cold Spring Harbor Laboratory Press; 2021; . Available from:
 442 https://www.medrxiv.org/content/10.1101/2021.06.14.21258872v1.abstract
- 38. Rue H, Held L. Gaussian Markov random fields: Theory and applications [Internet]. London,
 England: Chapman and Hall; 2004. Available from:
 https://www.taylorfrancis.com/books/mono/10.1201/9780203492024/gaussian-markov-randomfields-havard-rue-leonhard-held
- 447 39. Gomez-Rubio V. Bayesian inference with INLA. CRC Press; 2020.
- 40. Lindgren F, Rue H, Lindström J. An Explicit Link between Gaussian Fields and Gaussian
 449 Markov Random Fields: The Stochastic Partial Differential Equation Approach. J R Stat Soc
 450 Series B Stat Methodol. Oxford Academic; 2011; 73(4):423–498.
- 451
- 452
- 453 Footnotes

454 The authors would like to acknowledge funding from ERC 804744 and the CDC. The authors declare455 no conflicts of interest.

456

Figure 1 457





Figure 2



Figure 2: Estimated map of seropositivity. (A) Modelled seropositivity in Bangladesh in 2016 (B) Held out cross validation where communities were removed from model fitting process and the rest of the data used to fit models. The plot shows the comparison with the observed versus the predicted in the removed locations.

483 Table 1: Individual-, household- and community-level characteristics of participants across

484 Bangladesh, stratified by serostatus to chikungunya in 2015/16. Seropositivity determined based on 485 the presence of IgG antibodies against CHIKV.

	Ν	Seropositive	Seronegative	p-value*
		(N=69)	(N=2,869)	
Individual level	n	n (%)	n (%)	
Age (years):				N/A
<5	88	0 (0%)	88 (100%)	
5-10	341	7 (2%)	334 (98%)	
11-20	737	16 (2%)	721 (98%)	
21-30	518	12 (2%)	506 (98%)	
31-40	417	8 (2%)	409 (98%)	
41-50	367	10 (3%)	357 (97%)	
51-60	242	11 (5%)	231 (95%)	
>60	228	5 (2%)	223 (98%)	
Sex:				0.087
Female	1,532	43 (3%)	1,489 (97%)	
Male	1,406	26 (2%)	1,380 (98%)	
Dengue Status:				< 0.001
Seropositive	697	34 (5%)	663 (95%)	
Seronegative	2,237	35 (5%)	2,202 (98%)	
Unknown	4	0	4	
Last time left community:				0.8
δ180 days	1,704	41 (2%)	1,663 (98%)	
>180 days	1,234	28 (2%)	1,206 (98%)	
Household level				
Household income				0.8
(Taka, 100 Taka = 0.9				
USD):				
<10,000	850	18 (2%)	832 (98%)	
10,000-20,000	1,107	26 (2%)	26 (2%)	
>20,000	969	25 (3%)	25 (3%)	
Unknown	12	0	12	
Household head education:				0.6
No Education	908	23 (3%)	885 (97%)	
Primary School	759	14 (2%)	745 (98%)	
High School	797	20 (3%)	777 (97%)	

Higher	401	12 (3%)	389 (97%)	
Unknown	73	0	73	
Electricity in home:				0.3
No	187	4 (1%)	269 (99%)	
Yes	2,751	65 (2%)	2,600 (98%)	
Own home:				0.2
No	187	7 (4%)	180 (96%)	
Yes	2,751	62 (2%)	2,689 (98%)	
Own land away from the				0.016
home:				
No	598	22 (4%)	576 (96%)	
Yes	2,340	47 (2%)	2,293 (98%)	
Mosquito control used:				0.3
No	1,067	21 (2%)	1,046 (98%)	
Yes	1,871	48 (3%)	1,823 (97%)	
Community level				
Aedes aegypti captured:				< 0.001
No	1,973	33 (2%)	1,940 (98%)	
Yes	965	36 (4%)	929 (96%)	
Aedes albopictus captured:				0.5
No	1,707	43 (3%)	1,664 (97%)	
Yes	1,231	26 (2%)	1,205 (98%)	
Community type:				0.2
Rural	2,185	47 (2%)	2,138 (98%)	
Urban	753	22 (3%)	731 (97%)	
Division:				
Barisal	166	5 (3%)	161 (97%)	
Chittagong	779	18 (2%)	761 (98%)	
Dhaka	733	20 (3%)	713 (97%)	
Khulna	334	25 (7%)	309 (93%)	
Rajshahi	336	1 (1%)	335 (99%)	
Rangpur	462	0 (0%)	462 (100%)	
Sylhet	128	0 (0%)	128 (100%)	

486 *Pearson's Chi-squared test

488

489 Table 2: Results of univariate and multivariable logistic regression. The multivariable model 490 selected included random community and household intercepts, but no spatial field (Model 5), on the 491 basis of WAIC (Table S1).

	Univariate	Multivariable
Individual level	Odds ratio	Adjusted odds ratio
	(95% confidence interval)	(95% confidence interval)
Age group (years):		
<5	0.00 (0.00 - 1.58)	0.00 (0.00 - 0.0003)
5-10	0.99 (0.37 - 2.65)	1.06 (0.38 - 3.04)
11-20	REF	REF
21-30	1.01 (0.44 – 2.32)	0.71 (0.21 – 1.85)
31-40	0.96 (0.38 - 2.43)	0.70 (0.20 - 2.04)
41-50	1.42 (0.58 - 3.46)	1.63 (0.55 – 7.48)
51-60	2.13 (0.87 - 5.23)	3.35 (0.83 - 118.52)
>60	0.91 (0.30 - 2.75)	0.82 (0.24 - 2.67)
Sex:		
Female	REF	REF
Male	0.66 (0.31 – 1.17)	0.29 (0.01 - 0.96)
Dengue Status:		
Seronegative	REF	REF
Seropositive	2.06 (1.14 - 3.84)	3.11 (1.17 – 24.45)
Last time left community:		
≤180 days	REF	REF
>180 days	0.90 (0.51 - 1.57)	0.59 (0.06 - 1.42)
Household level		
Household income (Taka):		
<10,000	REF	REF
10,000 - 20,000	0.74 (0.38 - 1.49)	0.68 (0.11 – 1.81)
>20,000	1.25 (0.57 – 2.71)	2.63 (0.73 - 35.33)
Household head education:		
No education	REF	REF
Primary school	0.97 (0.39 – 2.33)	1.10 (0.42 - 2.88)
High school	0.77 (0.37 – 1.60)	0.75 (0.16 - 1.91)
Higher	0.62 (0.26 - 1.49)	0.62 (0.07 - 1.96)
Electricity in home:		

No	REF	REF		
Yes	1.46 (0.46 - 4.60)	1.93 (0.43 – 16.10)		
Own home:				
No	REF	REF		
Yes	0.25 (0.07 - 0.80)	0.06 (0.00 - 0.81)		
Own land away from home:				
No	REF	REF		
Yes	1.10 (0.56 – 2.12)	0.74 (0.34 – 1.62)		
Mosquito control:				
No	REF	REF		
Yes	0.67 (0.25 – 1.64)	0.44 (0.06 - 1.46)		
Community level				
A. aegypti captured:				
No	REF	REF		
Yes	5.52 (0.60 - 34.91)	3.52 (0.01 - 48.07)		
A. albopictus captured:				
No	REF	REF		
Yes	0.59 (0.08 - 6.29)	0.79 (0.09 - 15.79)		
Population density (log scale):	1.22 (0.63 – 2.51)	0.48 (0.05 – 1.36)		

494 **Supplementary figures**

495

496

497 Figure S1. Histogram of the ratios between fluorescence intensity to CHIKV and the control SNAP-tag protein with the cutoff point of 5.5 marked (dashed line). Samples to the left of the dashed 498

499 line are considered seronegative, and those to the right seropositive.





526 Figure S2: Difference in multivariable coefficient estimates. Run using logistic regression with a

527 Matérn spatial correlation structure, random community intercept and a random household intercept 528 (Model 1), a Matérn spatial correlation structure and random household intercept only (Model 2) a

529 Matérn spatial correlation structure and random community intercept only (Model 3), a Matérn spatial

correlation structure only (Model 4), and random household and community intercepts only (Model 5).

Figure S3.



Aedes albopictus Status





Table S1

Model	WAIC
1 (Spatial correlation structure, community	2190.89
intercept and household intercept)	
2 (Spatial correlation structure and random	3597.03
household intercept)	
3 (Spatial correlation structure and random	2306.11
community intercept)	
4 (Spatial correlation structure)	3771.10
5 (Community and household random intercepts)	496.22

Table S1: Model comparison

Table S2 547

	Multivariable
Individual level	Adjusted odds ratio (95%
	confidence interval)
Age group (years):	
<5	0.00 (0.00 - 0.0001)
5-10	1.06 (0.38 - 2.96)
11-20	REF
21-30	0.84 (0.35 - 2.00)
31-40	0.83 (0.32 – 2.17)
41-50	1.29 (0.52 – 3.23)
51-60	2.00 (0.78 - 5.13)
>60	0.88 (0.29 – 2.73)
Sex:	
Female	REF
Male	0.58 (0.33 - 1.02)
Dengue Status:	
Seronegative	REF
Seropositive	1.75 (0.94 – 3.25)
Last time left community:	
<180 days	REF
>180 days	0.83 (0.44 - 1.55)
Household level	
Household income (Taka):	
<10,000	REF
10,000 - 20,000	0.84 (0.38 - 1.85)
>20,000	1.51 (0.59 – 3.87)
Household head education:	
No education	REF
Primary school	1.01 (0.39 – 2.61)
High school	0.79 (0.35 – 1.80)
Higher	0.70 (0.27 – 1.82)
Electricity in home:	
No	REF
Yes	1.21 (0.33 - 4.48)
Own home:	
No	REF

Yes	0.30 (0.07 - 1.19)
Own land away from home:	
No	REF
Yes	1.07 (0.50 - 2.27)
Mosquito control:	
No	REF
Yes	0.60 (0.22 – 1.57)
Community level	
A. aegypti captured:	
No	REF
Yes	0.47 (0.08 - 2.61)
A. albopictus captured:	
No	REF
Yes	2.51 (0.44 - 14.8)
Population density (log scale):	0.89 (0.46 - 1.68)

Table S2: Results of logistic regression performed using data from the 16 communities with at 549 least one seropositive individual. 550

551 Table S3

	Univariate	Multivariable
Individual level	Odds ratio	Adjusted odds ratio
	(95% confidence interval)	(95% confidence interval)
Age group (years):		
<5	0.00 (0.00 - 4.11e7)	0.00 (0.00 - 6.42e6)
5-10	1.06 (0.39 - 3.11)	1.10 (0.39 - 3.10)
11-20	REF	REF
21-30	1.04 (0.45 - 2.56)	0.80 (0.33 - 1.94)
31-40	0.99 (0.38 - 2.74)	0.82 (0.29 - 2.21)
41-50	1.42 (0.57 - 3.78)	1.35 (0.53 - 3.46)
51-60	2.05 (0.83 - 5.36)	2.09 (0.76 - 6.88)
>60	0.98 (0.32 - 3.23)	0.90 (0.29 - 2.83)
Sex:		
Female	REF	REF
Male	0.74 (0.42 - 1.49)	0.55 (0.25 - 1.03)
Dengue Status:		
Seronegative	REF	REF
Seropositive	1.75 (0.89 - 3.24)	2.08 (1.01 - 6.52)
Last time left community:		
δ180 days	REF	REF
>180 days	1.18 (0.56 – 2.71)	0.75 (0.39 - 1.42)
Household level		
Household income (Taka):		
<10,000	REF	REF
10,000 - 20,000	0.73 (0.37 – 1.46)	0.82 (0.34 - 1.87)
>20,000	1.29 (0.59 - 2.81)	1.79 (0.68 - 4.82)
Household head education:		
No education	REF	REF
Primary school	0.96 (0.41 – 2.27)	1.07 (0.41 - 2.84)
High school	0.76 (0.37 – 1.56)	0.83 (0.36 - 1.90)
Higher	0.63 (0.26 - 1.47)	0.70 (0.25 - 1.91)
Electricity in home:		
No	REF	REF
Yes	1.28 (0.33 - 4.98)	1.31 (0.33 - 5.38)

	Own home:		
	No	REF	REF
	Yes	0.27 (0.06 - 0.96)	0.23 (0.04 - 1.00)
	Own land away from home:		
	No	REF	REF
	Yes	1.20 (0.63 - 2.30)	0.93 (0.42 - 2.18)
	Mosquito control:		
	No	REF	REF
	Yes	0.60 (0.22 – 1.51)	0.59 (0.22 - 1.52)
	Community level		
	A. aegypti captured:		
	No	REF	REF
	Yes	4.14 (0.46 - 39.24)	5.29 (0.26 - 215.30)
	A. albopictus captured:		
	No	REF	REF
	Yes	1.76 (0.31 – 11.15)	2.27 (0.16 - 30.23)
	Population density (log scale):	0.62 (0.00 - 2.41)	1.05 (0.39 - 2.68)
554	community intercept and a ran	dom household intercept.	-
554 555 556	community intercept and a ran	dom household intercept.	
554 555 556 557 558	community intercept and a ran	dom household intercept.	
554 555 556 557 558 559	community intercept and a ran	dom household intercept.	
554 555 556 557 558 559 560	community intercept and a ran	dom household intercept.	
554 555 556 557 558 559 560 561	community intercept and a ran	dom household intercept.	
554 555 556 557 558 559 560 561 562	community intercept and a ran	dom household intercept.	
554 555 556 557 558 559 560 561 562 563	community intercept and a ran	dom household intercept.	
554 555 556 557 558 559 560 561 562 563 563 564	community intercept and a ran	dom household intercept.	
554 555 557 558 559 560 561 562 563 563 564 565	community intercept and a ran	dom household intercept.	
554 555 557 558 559 560 561 562 563 564 565 566	community intercept and a ran	dom household intercept.	
554 555 557 558 559 560 561 562 563 564 565 566 566	community intercept and a ran	dom household intercept.	
554 555 556 557 558 559 560 561 562 563 564 565 566 566 567 568	community intercept and a ran	dom household intercept.	